Cantor Fitzgerald reiterated coverage on Longboard Pharmaceuticals with a new price target
$LBPH
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald reiterated coverage of Longboard Pharmaceuticals with a rating of Overweight and set a new price target of $90.00 from $60.00 previously